吉西他滨联合顺铂治疗Ⅲ、Ⅳ期非小细胞肺癌的临床评价

 目的 观察吉西他滨（GEM）联合顺铂（DDP）治疗Ⅲ、Ⅳ期非小细胞肺癌（NSCLC）的疗效及毒副反应。方法 2000年2月至2005年6月，对79例NSCLC患者采用GP方案化疗，用法：GEM 1000 mg／m2第1、8天给药；DDP 90 mg／m2分3 d，21 ~ 28 d为1周期，2 ~ 3周期评价疗效。结果 79例分别完成2～5周期联合化疗，其中完全缓解（CR）0例，部分缓解（PR）为25 %（20／79），稳定（SD）为27 %（21／79），临床受益反应（CBR）为52 %（41／79）。初治的39例中，CBR为56.4 %（22／39）；复治40例中， CBR为47.5 %（19／40）。毒副反应主要为血液学毒性，以血小板减少或白细胞数降低较为明显。结论 GEM联合DDP治疗Ⅲ、Ⅳ期NSCLC，具有良好的疗效及耐受性。

Clinical observation of stage Ⅲ, Ⅳ NSCLC treated by gemcitabine combined with cisplatin

Objective To observe the effects of gemcitabine combined with cisplatin regimen in stage III, IV non-small-cell lung cancer (NSCLC). Methods From February 2000 to June 2005, 79 patients with advanced NSCLC were treated with GP (GEMZAR 1000 mg/m2 d1,8; DDP 30 mg/m2 d1~3). The course was repeated every 3 weeks for at least 2~3 cycles. Results 2-5 cycles of chemotherapy were performed in all patients, the clinical benefit response (CBR) was 52 %(41/79), PR was 25 %(20/79), SD was 27 %(21/79). The clinical benefit response were 56.4 %(22/39) in the initiate group and 47.5 %(19/40) in the secondary group. Bone marrow suppression was the main toxicities, the major side effects were thrombocytopenia and leukope-nia. Conclusion The combination of gemcitabine and cisplatin is an effective and tolerable chemotherapy regimen for patients with advanced NSCLC.